Nanoparticle cross-linked collagen shields for sustained delivery of pilocarpine hydrochloride

Agban, Yosra; Lian, Jiaxin; Prabakar, Sujay; Seyfoddin, Ali; Rupenthal, Ilva D.

doi:10.1016/j.ijpharm.2016.01.069

Cited by 62 publications

(26 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[17] Collagen shields Agban et al described a novel a polyvinylpyrrolidone-capped zinc oxide (ZnO/PVP) collagen shield cross-linked with pilocarpine hydrochloride (PHCL). [18] They tested three different nanoparticles: Titanium dioxide, ZnO, and the ZnO/PVP, and compared various parameters essential for safe ocular use: Size, cytotoxicity, mechanical strength, transparency, swelling capacity, bioadhesive properties and concentration of ions released. They have shown that the ZnO/PVP, when prepared with a ratio of 1:1 between collagen to ZnO/PVP nanoparticles, was the leading candidate.…”

Section: Durasite Isv-215mentioning

confidence: 99%

Sustained drug delivery platforms – A new era for glaucoma treatment

Shouchane-Blum¹,

Geffen²,

Zahavi³

2019

cleverjournal

View full text Add to dashboard Cite

Glaucoma is a leading cause of blindness worldwide. Treatment typically consists of the chronic administration of topical eye drops. However, fluctuations in intraocular pressure, local and systemic side effects, and low patient compliance have prompted the development of various sustained drug delivery platforms, both extraocular and intraocular, over the last decade. Some are currently undergoing advanced clinical trials. Extraocular platforms include wearable ocular surface devices (such as ocular insert rings, topical ocular drug delivery devices, gel-forming eye drops, collagen shields, and contact lenses), punctal plugs (such as the OTX-TP and Latanoprost punctal plug delivery system), and subconjunctival injections (such as the EyeD VS-101, POLAT-001, GB-6249-103, IBI-60089, and dorzolamide-loaded polymer microparticles). Intraocular platforms include mainly intracameral implants (such as the Bimatoprost SR, ENV515 Travoprost XR, iDose, OTX-TIC, PA5108, and DE-117-loaded PLC), although other devices are drawing attention as potential treatment alternatives (such as intravitreal nanosponges and supraciliary implants). The purpose of this review is to describe these emerging sustained drug delivery systems for the treatment of glaucoma and ocular hypertension.

show abstract

Section: Durasite Isv-215mentioning

confidence: 99%

Sustained drug delivery platforms – A new era for glaucoma treatment

Shouchane-Blum¹,

Geffen²,

Zahavi³

2019

cleverjournal

View full text Add to dashboard Cite

show abstract

“…The synthesis of collagen in the body is made by fibroblast cells. Collagens possess good tensile strength, and found both outside and inside the body cells 9 . In combination with elastic, collagen provides support to body tissues and organs, basically collagen offers firmness and strength and elastic provides flexibility to body tissues.…”

Section: Collagenmentioning

confidence: 99%

Untitled

2017

IJPSR

View full text Add to dashboard Cite

Glaucoma is a disease of the optic nerve. Progressive damage of the optic nerve will causes irreversible reduction in visual acuity; it leads to visual field loss and blindness. The main treatment of glaucoma is the reduction of intraocular pressure. Current therapy involves frequent administration of eye drops which results in poor patient adherence and therapeutic outcomes. This review is focusing on to overcome these limitation by developing a novel nanoparticle crosslinked collagen shield for sustained delivery of suitable drug. The drug is incorporate into the shield and cross-linked by cross-linking agent with the help of Ultraviolet irradiation. Metal oxide nanoparticles is most suitable as cross-linking agent.e.g-polyvinylpyrrolidone (PVP) capped zinc oxide (ZnO/PVP).There is some evaluation parameter for nanoparticle cross-linked collagen shield like cytotoxicity as well as shield transparency. Cross-linked collagen shields characterise for their mechanical strength, swelling capacity and bioadhesive properties, ZnO/PVP NP cross-linked shields is the most favourable characteristics compare to plain film. It release drug over a period of 14 days offering a promising sustained release treatment option for glaucoma. The purpose of this review article is to provide information about novel Nanoparticle cross-linked collagen shield for sustained delivery of drug.

show abstract

“…Lipid nanoparticles [21] , Lipid-polymer hybrid nanoparticles [22] , Human serum albumin nanoparticles [23] have also been studied. Liposomes [24,25] and Microemulsions [26] have been developed for ophthalmic delivery.…”

Section: Introductionmentioning

confidence: 99%

Formulation and Characterization of Moxifloxacin Nanoparticles with Ion Exchange Resin

Vyas¹,

Daxini²,

Patel³

2020

J. Drug Delivery Ther.

View full text Add to dashboard Cite

Moxifloxacin (MOX) is a fluoroquinolone anti-infective drug, indicated for the treatment of bacterial conjunctivitis. The drug is soluble in water but still produces low ocular bioavailability due to biological barriers and so it requires dosing for two/three times a day. The present study was designed to formulate, optimize and characterize polymeric Nanoparticles MOX for ocular administration using Ion Exchange Resin (IER). IER-nanoparticles were prepared by media milling method, formulation/process parameters were optimized based on evaluation parameters such as color of nanosuspension, sedimentation behaviour, particle size and zeta potential. MOX-IER nanosuspensions were prepared at different stoichiometric ratio of MOX and IER and characterized by entrapment efficiency, pH, particle size and zeta potential of nanosuspension. In vitro release study of optimized batch MNIER3 exhibited sustained release pattern which follows Korsmeyer-Peppas model with Fickian diffusion mechanism for drug release. Based on these results optimized batch of MOX-IER nanosuspension formulated in the laboratory was found suitable for ocular delivery. Keywords: Moxifloxacin; nanoparticles, nanosuspension; media milling; stoichiometric ratio; sedimentation behaviour.

show abstract

Nanoparticle cross-linked collagen shields for sustained delivery of pilocarpine hydrochloride

Cited by 62 publications

References 36 publications

Sustained drug delivery platforms – A new era for glaucoma treatment

Sustained drug delivery platforms – A new era for glaucoma treatment

Untitled

Formulation and Characterization of Moxifloxacin Nanoparticles with Ion Exchange Resin

Contact Info

Product

Resources

About